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Abstract
Background: Multiple Sclerosis (MS) is the leading cause of non-traumatic neurological disability in
young adults. There is limited literature regarding the burden of MS in sub-Saharan Africa (SSA).
Objective: To describe the demographic and clinical characteristics of patients with MS (PwMS)
presenting to a tertiary referral hospital in Nairobi.
Methods: We conducted a retrospective descriptive study for PwMS presenting to Aga Khan University
Hospital, Nairobi from 2008–2018.
Results: 99 cases met the diagnostic criteria for MS with a male to female ratio of 1:4. Majority (68.7%)
of PwMS were indigenous Africans with a mean age of onset of 30.7 years. Mean duration from
symptom onset to first neuro-imaging was 5.04 years. Only 33% of patients had sensory symptoms at
onset whereas 54.5% had vitamin D deficiency/insufficiency. Majority (79.5%) had relapsing remitting
MS (RRMS) and 56.6% were initiated on disease modifying therapy (DMT). Only 21.2% of patients on
DMT were non-compliant. Patients with RRMS were more likely to be initiated on DMT at our hospital
(p < 0.001).
Conclusion: Clinical characteristics of these patients largely resemble those of other SSA cohorts and
African American patients. There was a delay between symptom onset and neuroimaging. There were
also issues with DMT compliance.
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Introduction
Multiple Sclerosis (MS) is the leading cause of progressive neurological disability in young adults1 and
has a huge impact on functional and financial
aspects of life.2 It is the most common immunemediated inflammatory demyelinating disease of
the central nervous system (CNS). The prevalence
of MS is high in Northern Europe, North America
and Australia. Recent data have questioned the conventional thinking of MS being more prevalent at
higher latitudes, with rising reports of MS morbidity
from regions with previously low prevalence.
MS seems to have a different phenotype depending
on race. For example, in one study, African
Americans were found to experience earlier onset

and faster disease progression than white
Americans.3 However, these differences were overestimated when there was no adjustment for socioeconomic factors. There have also been studies
demonstrating greater inflammatory activity within
the cerebrospinal fluid4 and more exacerbations in
African Americans compared to Caucasian
Americans with MS.5 There is little epidemiological
evidence of the MS phenotype in Africa and therefore it is difficult to ascertain whether it would be
similar or different to that described in the same
racial groups outside Africa.
In Kenya, there have only been 2 published MS case
series, totaling 15 patients.6,7 These patients were
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mainly female indigenous Africans, and usually presented with visual or sensory disturbances, but otherwise their disease progression and therapeutic
interventions were not evaluated. We have previously described 29 MS cases from a diagnostic audit at
our centre.8 We therefore set out to collect all the
cases of MS known to our hospital and describe the
findings here.

Materials and methods
Study setting
We conducted a descriptive study based on medical
records of MS patients from January 2008 to
December 2018 at the Aga Khan University
Hospital, Nairobi (AKUHN) and other sources
from affiliated neurologists (including neurologists
in private practice).
The study was approved by the Institutional Ethics
Review Board at AKUHN.
Case finding
We identified MS cases through (Figure 1):

(i) Medical record coding: our institution uses the
International Classification of Diseases (ICD10) coding system and we applied the G35
heading code for MS and all sub-codes to identify cases.

(ii) Pharmacy: we searched for patients who had
the following drugs and disease modifying therapies (DMTs) prescribed, which are the only
ones available in the country: interferon beta1a, glatiramer acetate, natalizumab, rituximab,
intravenous methylprednisolone (IVMP), and
azathioprine.
(iii) Laboratory: patients who had ever undergone
testing for cerebrospinal fluid oligoclonal
bands (CSF OCBs).
(iv) Neurophysiology: all patients who had had
visual evoked potentials (VEP).
(v) MS databases held by neurologists in the
hospital.
The cases identified from the above steps were collated and MS diagnoses then confirmed or rejected
based on the modified McDonald’s criteria.9 Neuroimaging including magnetic resonance imaging
(MRI) could only be done after identifying cases
through the above steps as our electronic data management and radiology reporting/archiving systems
do not have indexing mechanisms to allow searching
for particular keywords pertinent to MS. We excluded patients who were suspected to have MS but did
not have complete evaluation and therefore did not
meet the diagnostic criteria.
Data collection, management and analysis
We captured demographic variables (date of birth,
age, gender, race, marital status, migration status,
occupation), MS subtype [relapsing-remitting MS
(RRMS), primary progressive MS (PPMS) or

Figure 1. Potential patient identification using sampling steps 1–4.
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secondary progressive MS (SPMS)],10 symptoms at
presentation, comorbidities, and current as well as
previous medications, including DMTs. Important
dates recorded included date of onset of symptoms,
date of diagnosis, date of each documented relapse
and/or admission, date of the first clinic visit/admission at AKUHN (Visit 1), date of every MRI of the
CNS, and duration of DMT use. If available, we
recorded the expanded disability status scale
(EDSS)11 scores from the clinic notes.
The data were recorded in the form of an electronic
database and encrypted with a password which was
only known to the investigators. Categorical variables were expressed as frequencies and percentages,
continuous variables were expressed as means and
standard deviations. Univariate analysis was utilized
using the Chi Square (v2) or the Fisher’s Exact test
for DMT initiation in RRMS patients based on in
hospital or outside hospital and the Student’s t-test
or non-parametric equivalent tests for comparison of
EDSS scores between the first and last visit, RRMS
relapses per year based on pre-DMT vs post first
DMT, and time to first relapse according to the
type of MS. Normality of the continuous variables
was determined by the Shapiro Wilk test.
Correlation tests were performed using Spearman’s
Correlation test to associate factors with MS groups.
A p value of less than 0.05 was considered statistically significant. Data analysis was conducted using
IBM SPSS statistical software (Version 20).
Results
Patient characteristics
We identified 99 patients with MS between 20082018. Majority (79.8%) of the patients (n ¼ 79/99)
were female, giving a male-to-female ratio of 1:4,
and 70.1% of patients (n ¼ 68/99) were indigenous
black Africans (Table 1). The mean age of symptom
onset was 30.77 years [standard deviation (SD) ¼
10.03], while the mean age at diagnosis was
34.19 years (SD ¼ 11.36) (Table 1). Majority
(78.4%) of the patients (n ¼ 69/99) were employed
and working. Most of our patients had RRMS
(79.6%, n ¼ 78/99). More than half (54.5%) of the
patients (n ¼ 54/99) were diagnosed with MS when
they came to AKUHN, with the rest having their
diagnosis made elsewhere. The mean duration of
symptoms prior to diagnosis was 3.94 years
(SD ¼ 6.82).
About 61.6% of patients (n ¼ 61/99) had at least one
comorbid condition, the most common being
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Vitamin D insufficiency/deficiency (Table 1).
Approximately 20% of our patients (n ¼ 20/99) suffered from a psychiatric condition, most commonly
depression. Two patients had suffered from avascular necrosis of the hip(s) (See supplementary material for more information).
Clinical features
One-third (33.3%) of the symptoms at onset were
sensory in nature, while 29% had optic neuritis at
onset (Figure 2). 34% of patients (n ¼ 34/99) had 2
or more of the following features at onset: sensory
symptoms; weakness; optic neuritis; ataxia and vertigo; and Cranial nerve palsy. These symptoms were
also usually the same presenting features when the
patient first made contact with AKUHN, although
urinary symptoms were also more common (present
in 26.3% and 17.2% respectively). The mean duration between the first and second visit to AKUHN
was 7.8 months (SD ¼ 16.5). More than half (64.3%)
of the patients (n ¼ 63/99) who presented to
AKUHN had a relapse and 52% (n ¼ 51/99) were
first seen in the inpatient setting (Table 1). EDSS
scores were not reported within any of the clinic
notes.
Investigations
More than half (53%) of patients (n ¼ 52/99) had
their first MRI prior to first visiting AKUHN, of
which 42% (n ¼ 22/52) had enhancing lesions. The
mean duration from symptom onset to obtaining the
first MRI of the CNS was 5.04 years (SD ¼ 8.01)
(Table 1). Majority of the patients (91%; n ¼ 41/
45) who had their first MRI at AKUHN had enhancing lesions. Among patients who had their first MRI
prior to visiting AKUHN, 41% (41/52) met the
radiologic criteria of MS. Among patients who had
their first MRI at AKUHN, 82% (37/45) met the
radiologic criteria of MS.
During diagnostic evaluation, 63% of patients
(n ¼ 63/99) had CSF studies done, of which 39
patients were positive for CSF OCBs (as indicated
by an elevated IgG level in CSF of more than 34 mg/
l). There were no abnormalities in CSF white cell
counts and no organisms isolated in CSF culture. All
45% of patients (n ¼ 45/99) had VEPs done, of
which 20 were abnormal. A total of 7 patients
were evaluated for John Cunningham virus (JCV)
antibodies, of which 3 were positive, all of whom
were on natalizumab or rituximab.
Admissions and relapses
The mean number of visits to AKUHN was 8.29
(SD ¼ 8.84), while the mean number of admissions
3
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Table 1. Demographic characteristics of MS patients (n ¼ 99 unless otherwise stated).
Gender
Race (n ¼ 97)
Occupation (n ¼ 88)

Male
Female
African
Asian
Other
Working
Retired
Student (in school ¼ 6)
Unemployed

Family history of MS
Comorbidities

Vitamin D deficiency/insufficiency
Psychiatric illness
Others
Neurological/MS-related
Urologic
Migraine
Steroid-induced diabetes
Avascular necrosis of the hip
Seizures
Non-neurological
Age at diagnosis (n ¼ 98) [mean  SD]

20
79
68
16
13
69
6
12
1
5
54
20

20.20%
79.80%
70.10%
16.49%
13.40%
78.41%
6.82%
13.64%
1.14%
5.10%
54.55%
20.20%

17
7
4
2
2
2
82
34.19 (11.36)

17.17%
7.07%
4.04%
2.02%
2.02%
2.02%
82.82%

Age at onset of symptoms (n ¼ 91) [mean  SD]
Types of MS (n ¼ 98)
Relapsing-remitting MS
Secondary progressive MS
Primary progressive MS
CIS
Years from onset to diagnosis (n ¼ 91) [mean  SD]
Years from symptom onset to first MRI (n ¼ 85) [mean  SD]
CSF OCB (n ¼ 63)
Negative
Positive

30.77 (10.03)
78
15
4
1
3.94 (6.82)
5.04 (8.01)
24
39

38.10%
61.90%

VEP Result (n ¼ 45)

Normal
Abnormal
Inconclusive
Vitamin D levels (n ¼ 99)
Normala
Insufficientb
Deficientc
Vitamin B12 deficiency (n ¼ 65)
Negative
JCVd Antibodies (n ¼ 7)
Positive

24
20
1
16
29
25
3
4
3

53.33%
44.44%
2.22%
16.16%
29.29%
25.25%
4.62%
57.14%
42.60%

RRMS relapses/year

0.90 (0.93)
0.59 (0.60)
3.25 (6.29)
10.43 (7.15)

p ¼ 0.042f

Time to first relapsee

PreDMT
Post First DMT
RRMS (n ¼ 70)
SPMS (n ¼ 8)

79.59%
15.31%
4.08%
1.02%

p ¼ 0.005f

Normal Vitamin D:  30 ng/mL.
Vitamin D insufficiency: 20–29.9 ng/mL.
c
Vitamin D deficiency: < 20 ng/mL.
d
JCV: John Cunningham Virus.
e
Relapse data for SPMS relates to relapses that occurred prior to progression of MS.
f
Statistically significant (p<0.05).
a

b
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Figure 2. Symptoms at onset and at the first AKUHN visit.

during the study period was 1.85 (SD ¼ 2.27). The
mean duration to first relapse was 3.99 years
(SD ¼ 6.66). The most common reason for admission was relapse investigation and treatment
(51.6%), followed by rituximab infusion (18.6%)
and diagnostic workup (16.3%).
The overall relapse rate was 0.79/year in RRMS
patients, and 0.10/year for SPMS. Majority of the
relapses occurred while off a DMT (72.7%). The
relapse rate after DMT commencement was significantly lower than the relapse rate before DMT (0.59
vs 0.90 relapses/year, p ¼ 0.042) (Table 1).
Two patients underwent plasma exchange as relapse
treatment, while the rest of the patients received
IVMP for relapses.
Disease modifying therapies
The mean duration between MS diagnosis and to
starting DMT was 22.2 months (SD ¼ 37.9) for
RRMS patients and 69.8 months (SD ¼ 79.9) for
SPMS patients in the cohort. Most of the patients
(82.65%; 81/99) had not received DMT prior to
their first visit to AKUHN, of which 81.5%
(n ¼ 66/81) were RRMS patients (Table 2). Of the
patients who had received DMT prior to their first
visit in AKUHN (n ¼ 17/99), 5 patients had SPMS.
About 32 patients (48.5%) with RRMS had DMTs
initiated for the first time when they visited
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AKUHN. Approximately 48% of patients (n ¼ 47/
99) never received DMT at all, of which 34 had
RRMS. Visiting AKUHN was significantly associated with DMT initiation (p < 0.001) (Table 2).
Sixteen patients experienced challenges in maintaining adherence to DMTs, intolerance (11 patients),
and financial toxicity of DMTs (5 patients) being
the most common reasons. Eleven patients were
noncompliant to DMT, commonly due to financial
constraints.
The most commonly prescribed DMT was interferon
beta 1 A (55.7%), followed by glatiramer acetate
(15.38%) (Figure 3).
Missing data
The variables with large amounts of missing data
included results of relevant investigations done
prior to visiting AKUHN, such as MRI and CSF
results, and EDSS values were not evaluated in
any of the patients.
Discussion
This is the largest registry cohort to date from
Kenya. MS presented predominantly with opticospinal disease at onset. RRMS was the most common
type of MS. Neuroimaging, and thereby, diagnosis
was delayed by 5 years. Relapses were predominantly treated with IVMP. Patients with RRMS were
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Table 2. DMT use in MS patients – Placed after section on disease modifying therapies.
Patients who received DMT prior to Visit 1 (n ¼ 98)
Relapsing MS
Progressive MS
Patients on DMT on contact with AKUHN (n ¼ 97)
Relapsing MS
Progressive MS
Patients first DMT initiated at AKUHN (n ¼ 98)
Relapsing MS
Progressive MS
PPMS
SPMS
Patients DMT usage at last visit
On DMT
Not on DMT
DMT initiation in RRMS patients
Ever
PREAKUHN
11
AKUHN
37
Total
48
Specific challenges with DMT (n ¼ 20 from 16 patients)
Intolerance
Financial issues
Drug unavailability
Pregnancy
Others
Reasons for non-compliance (n ¼ 11) Unknown
Cost/financial difficulty
Stress
Wants to change DMT
Parent not available to inject
Unavailability of smaller needles for injection

12
5

12.24%
5.10%

6
2
36
32
4
0
4
40
59
Never
67
41
108

6.19%
2.06%
36.73%

11
5
2
1
1
5
2
1
1
1
1

55.00%
25.00%
10.00%
5.00%
5.00%
45.45%
18.18%
9.09%
9.09%
9.09%
9.09%

40.40%
59.60%
Total
78
78
156

Figure 3. DMT used by patients with MS.
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more likely to be initiated on DMT (mostly interferon beta 1a), after which there were notable issues
with adherence.
Demographics and comorbidities
Our registry cohort is similar to others in SSA. The
female to male ratio of 4:1 is comparable to the sex
ratio of 7:2 found in a small study conducted in
Nairobi,6 although a higher female preponderance
has been found in AA.12,13 Most of our patients
were indigenous black Africans. This is in contrast
to previous studies in South Africa, whereby majority of the patients are white, with blacks constituting
a minority.14–16 The study in Sudan mainly involved
patients of Arab-African ethnicity.17
The majority of our patients had comorbidities especially psychiatric – mainly depression – which is a
known common comorbidity generally in MS.18
Over half (54%) of our patients had vitamin D insufficiency/deficiency; although the MS Sunshine
Study concluded Vitamin D was not associated
with MS risk, duration of UV exposure was which
may be relevant to our finding.19
Other common comorbidities in our cohort included
dyslipidemia, thyroid disorders (goitre/hypothyroidism) and vitamin B12/folic acid deficiency.
According to meta-analyses, the most prevalent
comorbidities in PwMS were depression, anxiety,
hypertension, hyperlipidemia and chronic lung disease.18 Meningiomas, inflammatory bowel disease
and irritable bowel syndrome, epilepsy, early cataracts and restless legs syndrome were also found to
be more common than expected in the MS population. In contrast, only 2% and 3% of this cohort
suffered from epilepsy and restless legs syndrome
respectively. Only 4 of our patients had
vitamin B12 deficiency. Although vitamin B12 deficiency leads to demyelination, the association
with MS is somewhat unclear. Majority of patients
with MS do not have detectable vitamin B12
deficiency.20
Only 9% of our patients had a history of tobacco
smoking. In meta-analyses, smoking has a significant association with MS risk. Possible mechanisms
for this include increased blood-brain barrier permeability, cyanide-related CNS demyelination and
nitric oxide-related axonal degeneration and conduction block.21
Two of our patients had a history of unilateral/bilateral hip avascular necrosis (AVN). However, the
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aetiology of AVN was not clearly documented in
the patient charts. Both patients had 5–6 relapses.
It is most likely that these could be steroid-related.
There have been a number of case reports and case
series describing AVN in PwMS.22
Clinical and diagnostic characteristics
The mean age of onset of symptoms was 30.7 years
with a delay of 4 years to diagnosis. This is comparable to e.g. Nigeria,23 but the delay-to-diagnosis is
twice as long when compared to e.g. a 2006 study in
North America which revealed a delay of
2.2 years.12 Approximately 80% of our patients
had RRMS which is more than the globally reported
mean.24 Most of our patients had weakness, sensory
symptoms or optic neuritis which is similar to the
other study from Kenya6 and Nigeria.23
Only five percent of our patients had a positive
family history of MS. Familial aggregation of
PwMS has commonly been described in areas of
high prevalence, such as Europe,25–27 as well is in
the Middle East and North Africa (MENA) region28
which is thought to be due to a higher consanguineous marriage rate. Globally, the prevalence of
familial MS is estimated at 12.6%.29
The delay from symptom onset to first MRI was
5.04 years, and 53% of patients had their first MRI
at another facility prior to visiting AKUHN. This
reflects the relative lack of availability of MRI diagnostic services in our region, compounded by probably missed diagnoses due to a severe scarcity of
neurologists. There are only 18 neurologists in
Kenya for a population of 50 million and most are
based in the capital. In the other study from Nairobi,
5 of the 9 patients had travelled abroad specifically
for MRI scanning,6 reflecting that there has indeed
been a rise of MRI diagnostics over the last two
decades but there is still a large gap in service.
Most patients (76%) had not had CSF studies done
prior to their first visit to AKUHN. In Sudan, only
selected patients underwent CSF OCB and VEP testing due to decreased access to such diagnostics.17
After visiting our institution, and additional 39%
underwent CSF analysis, with our laboratory being
one of the few in the region that offer OCB testing.
DMT role, compliance and challenges
The time to first relapse was significantly shorter in
the RRMS group than the SPMS group. Patients
were more likely to receive DMT at our facility as
compared to another facility, probably due to our
hospital having the highest concentration of
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neurologists compared to any other centre in the
capital. The mean duration from MS diagnosis to
initiation of DMT was 22.2 months; interestingly
some patients were started on DMT even before
the diagnosis was confirmed as reflected in SD.
Data from the Big MS Data Network suggests that
DMT should be initiated within 6 months from disease onset in order to prevent long-term disability.30
Two important effects from visiting our institution
were noted: the increased DMT prescribing translated to few documented relapses in the RRMS group,
and patients on DMTs were more likely to stay on
them at last follow-up.
Interestingly, 4 patients with SPMS had DMTs initiated too, which is less than those SPMS patients on
DMTs before they came to our hospital (reflecting
the non-specialist care they could have been receiving). On personal review of these cases with the
neurologists concerned, it seemed the main reason
was that these cases were under the ambiguous
“relapsing-progressive” category, one which does
not help on DMT decision making. However, the
category relapsing-progressive MS has been eliminated and is no longer used.10
More than half, 34 of 47 patients (53%) who had
never received DMT had RRMS. Comparatively, in
a study in Nigeria, 3 out of 5 patients were on DMT
(60%),23 and none of the Sudanese cohort received
DMT as the agents were not locally available.17
DMT availability is much higher (mean of 77%)
in high-income countries as well is in the MENA
region.6
DMTs are available in Kenya for PwMS. However,
data on accessibility to DMT in Kenya is lacking,
especially in the government healthcare facilities.
Despite the availability of DMT in our institution
(private), 21% of our patients were noncompliant,
most commonly due to financial constraints. Studies
looking at adherence to IFNB and glatiramer acetate,
indicate that 60–70% of patients adhere to treatment
for 2–5 years,31 and the usual reason for not continuing was due to the discomfort or reluctance of selfinjecting. The costs of DMT for MS in the United
States have been shown to be high and rising with
time. This has been a major concern among health
care providers and patients.28
The most commonly initiated DMT in AKUHN was
IFNB (33.8%), followed by rituximab (20.97%).
We have looked at our registry since the completion
of this study and rituximab is now the most
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commonly prescribed DMT at our institution. This
is because it is readily available at our institution and
is the most cost-effective and convenient DMT for
patients.
Limitations of this study include the generalizability
of results and missing data. The study was conducted
in a private tertiary health facility whereby patients
of different nationalities are seen, unlike that in most
public healthcare facilities in Kenya. This study
probably therefore, would not be representative of
the state of MS in the country as a whole. Given
the retrospective nature of this study, missing data
was also a challenge, especially for laboratory
results that were done prior to the availability of
an electronic data system in our institution. In addition, there were no EDSS scores on any of the medical records that were reviewed.

Conclusion
MS in Kenya is not rare and the overall phenotype is
similar to other countries in Africa and blacks in
North America. The majority of our cohort has
RRMS. There was no difference in disability
between native black Africans and other races at
their first visit to AKUHN. There was a significant
delay between symptom onset and neuroimaging,
which leads to a delay in diagnosis and treatment.
There was also a prolonged duration between diagnosis and initiation of DMT. Relapse rates were
reduced after introduction of DMT. Relapses were
mainly treated with IVMP.
This study demonstrates similarities between MS
patients at AKUHN and AA PwMS in North
America, and also highlights key challenges regarding DMT availability and compliance in our patients.
Given that our patient population was heterogeneous, it is important to have more studies conducted
in government health facilities, in order for us to
have a better understanding of MS in the Kenyan
population. In addition, creation of a national MS
registry would enable us to have a database of
patients, for further research and for more comprehensive care, and encourage government agencies to
participate in making DMT more widely accessible.
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